April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
January 2025 in “The Journal of Dermatology” Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
7 citations
,
November 2023 in “JAAD Case Reports” This case series explores the efficacy of baricitinib, a JAK1/2 inhibitor, in treating severe alopecia areata (AA) in 3 patients who previously failed other JAK inhibitor therapies. The study found that baricitinib led to significant hair regrowth in these patients, with improvements in the Severity of Alopecia Tool (SALT) scores. Despite prior failures with JAK inhibitors like tofacitinib and upadacitinib, baricitinib showed potential benefits, suggesting that differences in JAK selectivity and pharmacologic properties may influence treatment outcomes. The study highlights the need for further research to identify patient characteristics that predict better responses to specific JAK inhibitors. Limitations include the small sample size and short follow-up period.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
57 citations
,
August 2023 in “American Journal of Clinical Dermatology” JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
44 citations
,
November 2016 in “Journal of The American Academy of Dermatology” The updated SALT II tool offers a more precise way to measure scalp hair loss.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
